期刊论文详细信息
BMC Musculoskeletal Disorders
Why PRP works only on certain patients with tennis elbow? Is PDGFB gene a key for PRP therapy effectiveness? A prospective cohort study
Anna Balcerzyk1  Iwona Żak1  Joanna Iwanicka1  Paweł Niemiec1  Alicja Jarosz1  Tomasz Iwanicki1  Tomasz Nowak1  Wojciech Garczorz2  Tomasz Francuz2  Sylwia Górczyńska-Kosiorz3  Władysław Grzeszczak3  Wojciech Kania4  Karol Szyluk5  Marcin Kalita5  Marius Negru6 
[1] Department of Biochemistry and Medical Genetics, School of Health Sciences in Katowice, Medical University of Silesia in Katowice, Medyków 18 str, 40-752, Katowice, Poland;Department of Biochemistry, School of Medicine in Katowice, Medical University of Silesia in Katowice, Medyków 18 str, 40-752, Katowice, Poland;Department of Internal Medicine, Diabetology and Nephrology, School of Medicine, Division of Dentistry in Zabrze, Medical University of Silesia in Katowice, 41-800, Zabrze, Poland;Department of Trauma and Orthopedic Surgery, Multidisciplinary Hospital in Jaworzno, Chełmońskiego 28 Str, 43-600, Jaworzno, Poland;District Hospital of Orthopaedics and Trauma Surgery, Bytomska 62 str, 41-940, Piekary Śląskie, Poland;Trauma and Orthopaedics Departament, St. Bernard’s Hospital, Harbour Views Rd, GX11 1AA, Gibraltar, UK;
关键词: Platelet-rich plasma;    Tennis elbow;    Tendinopathy;    PDGFB;    single nucleotide polymorphisms, gene;   
DOI  :  10.1186/s12891-021-04593-y
来源: Springer
PDF
【 摘 要 】

BackgroundThere is variability in individual response to platelet-rich plasma (PRP) therapy in tennis elbow treatment. Genetic variation, especially within genes encoding growth factors may influence the observed inter-individual differences. The purpose of this study was to identify polymorphic variants of the platelet-derived growth factor beta polypeptide gene (PDGFB) that determine an improved individual response to PRP therapy in tennis elbow patients.MethodsThis prospective cohort study was designed in accordance with STROBE and MIBO guidelines. A cohort of 107 patients (132 elbows, 25 bilateral) was studied, including 65 females (77 elbows) and 42 males (55 elbows), aged 24–64 years (median 46.00 ± 5.50), with lateral elbow tendinopathy treated with autologous PRP injection. The effectiveness of PRP therapy was recorded in all subjects at 2, 4, 8, 12, 24 and 52 weeks after PRP injection using the Visual Analog Scale (VAS), quick version of Disabilities of the Arm, Shoulder and Hand score (QDASH) and Patient-Rated Tennis Elbow Evaluation (PRTEE). In order to determine the PDGFB variants with the best response to PRP therapy, patient reported outcome measures were compared between individual genotypes within studied polymorphic variants (rs2285099, rs2285097, rs2247128, rs5757572, rs1800817 and rs7289325). The influence of single nucleotide polymorphisms on blood and PRP parameters, including the concentration of PDGF-AB and PDGF-BB proteins was also analyzed.ResultsOur analysis identified genetic variants of the PDGFB gene that lead to a better response to PRP therapy. The TT (rs2285099) and CC (rs2285097) homozygotes had higher concentration of platelets in whole blood than carriers of other genotypes (p = 0.018) and showed significantly (p < 0.05) lower values of VAS (weeks 2–12), QDASH and PRTEE (weeks 2–24). The rs2285099 and rs2285097 variants formed strong haplotype block (r2 = 98, D’=100). The AA homozygotes (rs2247128) had significantly lower values of VAS (weeks 4–52), QDASH and PRTEE (weeks 8, 12).ConclusionsPDGFB gene’s polymorphisms increase the effectiveness of PRP therapy in tennis elbow treatment. Genotyping two polymorphisms of the PDGFB gene, namely rs2285099 (or rs2285097) and rs2247128 may be a helpful diagnostic tool while assessing patients for PRP therapy and modifying the therapy to improve its effectiveness.

【 授权许可】

CC BY   

【 预 览 】
附件列表
Files Size Format View
RO202109179228211ZK.pdf 1174KB PDF download
  文献评价指标  
  下载次数:0次 浏览次数:2次